To the Editor I read with interest the systematic review and meta-analysis in JAMA Psychiatry by Menegaz de Almeida et al, which reveals that bright light therapy (BLT) was an effective adjunctive treatment for nonseasonal depressive disorders. For this systematic review, trials were systematically searched from inception to March 25, 2024, and finally, 11 studies were included in this meta-analysis. I do not understand why the study by Hirakawa et al was not included. The study, published in December 2023, was a 4-week randomized clinical trial conducted on patients with mood disorders (including depression and bipolar disorder). Patients were randomly assigned to either a bright light exposure group (BL group; 10 000 lux) or a dim light exposure group (DL group; 50 lux). Although the primary outcome of our study was to investigate the effects of light therapy on the hippocampal dentate gyrus, we also assessed the change in clinical symptoms, evaluated using the 17-Item Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) as a secondary outcome. The final sample in Hirakawa et al included 24 patients with mood disorders (BL group, n = 12; DL group, n = 12). In the BL group, the mean HAM-D score decreased from 9.1 to 4.9, and the mean BDI score decreased from 18.6 to 7.6 after 4 weeks of BLT. In the DL group, the mean HAM-D score decreased from 9.8 to 7.6, and the mean BDI score decreased from 20.9 to 14.3 after 4 weeks of BLT. Additionally, I can provide the response rate and remission rate for each group on reasonable request from the author.